Donald A. Zakrowski
Known title: Chief Accounting OfficerCIK: 0001561539
Associated companies
Transaction History
| LLY | ▼ Sell | Open Market | 2,000 | $2.4M | 8/10/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 184 | $0 | 2/16/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 82 | $85K | 2/16/2026 | View on chart |
| LLY | ▲ Buy | Grant | 584 | $610K | 2/9/2026 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $1.0M | 11/13/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $735K | 8/28/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $716K | 5/27/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $818K | 3/13/2025 | View on chart |
| LLY | ▲ Buy | Grant | 1,360 | $1.2M | 2/10/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 900 | $723K | 11/8/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 750 | $713K | 8/26/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 750 | $615K | 6/3/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 750 | $565K | 3/11/2024 | View on chart |
| LLY | ▲ Buy | Grant | 1,254 | $925K | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,810 | $0 | 12/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,142 | $1.3M | 12/1/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 670 | $383K | 11/6/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 600 | $328K | 8/21/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 600 | $261K | 5/15/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 600 | $193K | 2/27/2023 | View on chart |
| LLY | ▲ Buy | Grant | 1,904 | $657K | 2/10/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $301K | 9/1/2022 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $313K | 6/1/2022 | View on chart |
| LLY | ▼ Sell | Open Market | 1,660 | $405K | 2/25/2022 | View on chart |
| LLY | ▲ Buy | Grant | 2,947 | $717K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.